PMID- 36551989
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221225
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 10
IP  - 12
DP  - 2022 Dec 12
TI  - Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience.
LID - 10.3390/biomedicines10123229 [doi]
LID - 3229
AB  - Pirfenidone and nintedanib are the only two drugs approved for the treatment of 
      idiopathic pulmonary fibrosis (IPF). Both proved to be safe and well-tolerated in 
      clinical trials, but real-world data and direct comparisons are scarce. This 
      real-life study explored the safety profile of pirfenidone and nintedanib with a 
      prolonged follow-up. We retrospectively collected clinical status, adverse events 
      (AEs), and treatment changes from IPF patients who had started an antifibrotic 
      treatment at our centre from December 2011 to December 2020, including 192 
      patients treated with pirfenidone and 89 with nintedanib. The majority of 
      patients in both groups experienced one or more AEs during the follow-up. A 
      higher proportion of AEs in the nintedanib group were effectively treated with 
      behavioural modifications or additional medications compared with the pirfenidone 
      group (52.5% vs. 40.6%, p = 0.04). Overall, a difference in the impact of AEs due 
      to nintedanib versus pirfenidone resulted in a lower permanent discontinuation of 
      therapy (8.3% vs. 18.3%, p = 0.02), with the latter being associated with a 
      higher risk of drug discontinuation at 48 months after initiation (OR = 2.52, p = 
      0.03). Our study confirms the safety profile of antifibrotic drugs in IPF but 
      highlights that AEs due to nintedanib are usually easier to manage and lead to 
      fewer cases of permanent discontinuation of therapy.
FAU - Levra, Stefano
AU  - Levra S
AD  - Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, 
      Italy.
FAU - Guida, Giuseppe
AU  - Guida G
AUID- ORCID: 0000-0003-3876-8587
AD  - Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, 
      Italy.
AD  - Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, 
      Orbassano, 10043 Turin, Italy.
FAU - Sprio, Andrea Elio
AU  - Sprio AE
AUID- ORCID: 0000-0001-5891-871X
AD  - Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, 
      Italy.
FAU - Crosa, Flavio
AU  - Crosa F
AD  - Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, 
      Orbassano, 10043 Turin, Italy.
FAU - Ghio, Paolo Carlo
AU  - Ghio PC
AD  - Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, 
      Orbassano, 10043 Turin, Italy.
FAU - Bertolini, Francesca
AU  - Bertolini F
AUID- ORCID: 0000-0003-4390-0394
AD  - Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, 
      Italy.
FAU - Carriero, Vitina
AU  - Carriero V
AD  - Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, 
      Italy.
FAU - Albera, Carlo
AU  - Albera C
AUID- ORCID: 0000-0002-0334-869X
AD  - Department of Medical Sciences, University of Turin, 10124 Turin, Italy.
AD  - Division of Respiratory Medicine, Cardiovascular and Thoracic Department, AOU 
      Citta della Salute e della Scienza di Torino, 10126 Turin, Italy.
FAU - Ricciardolo, Fabio Luigi Massimo
AU  - Ricciardolo FLM
AUID- ORCID: 0000-0003-1826-5018
AD  - Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, 
      Italy.
AD  - Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, 
      Orbassano, 10043 Turin, Italy.
AD  - Institute of Translational Pharmacology, National Research Council (IFT-CNR), 
      Section of Palermo, 90146 Palermo, Italy.
LA  - eng
PT  - Journal Article
DEP - 20221212
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC9775369
OTO - NOTNLM
OT  - idiopathic pulmonary fibrosis
OT  - nintedanib
OT  - pirfenidone
OT  - real-life
COIS- Fabio L.M. Ricciardolo reports grants from AstraZeneca, Chiesi, GSK, Novartis, 
      and Sanofi, all outside of the submitted work. Carlo Albera served as advisor, 
      principal investigator in clinical trials, steering committee member, and 
      received personal fees and unrestricted grants from Boehringer Ingelheim, ROCHE, 
      and Fibrogen. All other authors declare no conflicts of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/12
CRDT- 2022/12/23 01:13
PHST- 2022/08/12 00:00 [received]
PHST- 2022/11/11 00:00 [revised]
PHST- 2022/12/07 00:00 [accepted]
PHST- 2022/12/23 01:13 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/12 00:00 [pmc-release]
AID - biomedicines10123229 [pii]
AID - biomedicines-10-03229 [pii]
AID - 10.3390/biomedicines10123229 [doi]
PST - epublish
SO  - Biomedicines. 2022 Dec 12;10(12):3229. doi: 10.3390/biomedicines10123229.